Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Gross Profit 2011-2025 | IRWD

Ironwood Pharmaceuticals gross profit from 2011 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Ironwood Pharmaceuticals Annual Gross Profit
(Millions of US $)
2024 $351
2023 $443
2022 $411
2021 $414
2020 $386
2019 $405
2018 $314
2017 $279
2016 $272
2015 $150
2014 $71
2013 $16
2012 $149
2011 $66
2010 $44
Ironwood Pharmaceuticals Quarterly Gross Profit
(Millions of US $)
2025-06-30 $85
2025-03-31 $41
2024-12-31 $91
2024-09-30 $92
2024-06-30 $94
2024-03-31 $75
2023-12-31 $118
2023-09-30 $114
2023-06-30 $107
2023-03-31 $104
2022-12-31 $107
2022-09-30 $109
2022-06-30 $97
2022-03-31 $98
2021-12-31 $117
2021-09-30 $104
2021-06-30 $104
2021-03-31 $89
2020-12-31 $116
2020-09-30 $103
2020-06-30 $89
2020-03-31 $78
2019-12-31 $115
2019-09-30 $131
2019-06-30 $91
2019-03-31 $68
2018-12-31 $109
2018-09-30 $61
2018-06-30 $77
2018-03-31 $67
2017-12-31 $85
2017-09-30 $81
2017-06-30 $62
2017-03-31 $52
2016-12-31 $87
2016-09-30 $66
2016-06-30 $54
2016-03-31 $66
2015-12-31 $53
2015-09-30 $40
2015-06-30 $28
2015-03-31 $29
2014-12-31 $45
2014-09-30 $17
2014-06-30 $-4
2014-03-31 $13
2013-12-31 $4
2013-09-30 $3
2013-06-30 $6
2013-03-31 $2
2012-12-31 $27
2012-09-30 $96
2012-06-30 $15
2012-03-31 $12
2011-12-31 $32
2011-09-30 $12
2011-06-30 $11
2011-03-31 $10
2010-12-31 $17
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.333B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $74.015B 28.11
Zoetis (ZTS) United States $52.689B 18.86
Takeda Pharmaceutical (TAK) Japan $43.402B 8.86
Daiichi Sankyo, - (DSNKY) Japan $41.941B 20.89
BeOne Medicines - (ONC) Switzerland $36.448B 193.23
Sandoz Group AG (SDZNY) Switzerland $29.586B 0.00
United Therapeutics (UTHR) United States $19.548B 17.20
Merck (MKKGY) Germany $16.433B 10.69
Neurocrine Biosciences (NBIX) United States $15.434B 37.03
Shionogi (SGIOY) Japan $14.445B 13.27
Summit Therapeutics (SMMT) United States $14.228B 0.00
Ionis Pharmaceuticals (IONS) United States $12.002B 0.00
IPSEN (IPSEY) France $11.841B 0.00
Madrigal Pharmaceuticals (MDGL) United States $11.096B 0.00
Orion OYJ (ORINY) Finland $8.793B 25.12
Eisai (ESAIY) $8.166B 0.00
Corcept Therapeutics (CORT) United States $7.685B 83.02
Stevanato Group S.p.A (STVN) Italy $7.392B 41.37
Grifols, S.A (GRFS) Spain $5.748B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.730B 17.43
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.549B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $4.173B 0.00
Crinetics Pharmaceuticals (CRNX) United States $4.096B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $3.662B 17.40
Centessa Pharmaceuticals (CNTA) United Kingdom $3.058B 0.00
Hypermarcas (HYPMY) Brazil $2.899B 21.80
Dyne Therapeutics (DYN) United States $2.600B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.580B 8.23
Soleno Therapeutics (SLNO) United States $2.339B 0.00
Ocular Therapeutix (OCUL) United States $2.265B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.839B 21.80
Avadel Pharmaceuticals (AVDL) Ireland $1.817B 0.00
Guardian Pharmacy Services (GRDN) United States $1.804B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.480B 87.88
Ardelyx (ARDX) United States $1.373B 0.00
Collegium Pharmaceutical (COLL) United States $1.281B 6.36
Harrow (HROW) United States $1.274B 0.00
Xeris Biopharma Holdings (XERS) United States $1.245B 0.00
Oruka Therapeutics (ORKA) United States $1.175B 0.00
Evotec AG (EVO) Germany $1.174B 0.00
Relay Therapeutics (RLAY) United States $1.126B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.111B 0.00
Enliven Therapeutics (ELVN) United States $1.084B 0.00
Nektar Therapeutics (NKTR) United States $1.048B 0.00
Xencor (XNCR) United States $1.000B 0.00
Cronos Group (CRON) Canada $0.946B 0.00
ProKidney (PROK) United States $0.827B 0.00
ARS Pharmaceuticals (SPRY) United States $0.810B 0.00
Theravance Biopharma (TBPH) United States $0.749B 61.96
Aquestive Therapeutics (AQST) United States $0.748B 0.00
Savara (SVRA) United States $0.688B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.656B 5.85
Elite Pharmaceuticals (ELTP) United States $0.645B 0.00
Bioventus (BVS) United States $0.618B 12.68
Siga Technologies (SIGA) United States $0.585B 8.01
KalVista Pharmaceuticals (KALV) United States $0.550B 0.00
Akebia Therapeutics (AKBA) United States $0.533B 0.00
Zevra Therapeutics (ZVRA) United States $0.512B 0.00
4D Molecular Therapeutics (FDMT) United States $0.510B 0.00
Esperion Therapeutics (ESPR) United States $0.504B 0.00
Organogenesis (ORGO) United States $0.493B 0.00
Lexeo Therapeutics (LXEO) United States $0.455B 0.00
Galectin Therapeutics (GALT) United States $0.360B 0.00
USANA Health Sciences (USNA) United States $0.350B 9.78
Altimmune (ALT) United States $0.348B 0.00
Lyell Immunopharma (LYEL) United States $0.344B 0.00
Korro Bio (KRRO) United States $0.306B 0.00
Aldeyra Therapeutics (ALDX) United States $0.289B 0.00
Larimar Therapeutics (LRMR) United States $0.287B 0.00
Pyxis Oncology (PYXS) United States $0.252B 0.00
Aclaris Therapeutics (ACRS) United States $0.246B 0.00
Achieve Life Sciences (ACHV) Canada $0.242B 0.00
Nature's Sunshine Products (NATR) United States $0.242B 14.30
Journey Medical (DERM) United States $0.242B 0.00
AleAnna (ANNA) United States $0.219B 0.00
Avalo Therapeutics (AVTX) United States $0.203B 0.00
Heron Therapeutics (HRTX) United States $0.202B 0.00
MediWound (MDWD) Israel $0.200B 0.00
OmniAb (OABI) United States $0.199B 0.00
Profound Medical (PROF) Canada $0.177B 0.00
Innate Pharma SA (IPHYF) France $0.168B 0.00
China SXT Pharmaceuticals (SXTC) China $0.166B 0.00
Protara Therapeutics (TARA) United States $0.166B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.153B 0.00
Cassava Sciences (SAVA) United States $0.143B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.128B 0.00
Incannex Healthcare (IXHL) Australia $0.127B 0.00
Inhibikase Therapeutics (IKT) United States $0.111B 0.00
Surrozen (SRZN) United States $0.107B 0.00
Cardiol Therapeutics (CRDL) Canada $0.101B 0.00
Context Therapeutics (CNTX) United States $0.098B 0.00
Champions Oncology (CSBR) United States $0.095B 34.40
Vivani Medical (VANI) United States $0.093B 0.00
Avita Medical (RCEL) United States $0.091B 0.00
VAXART, INC (VXRT) United States $0.087B 0.00
Relmada Therapeutics (RLMD) United States $0.087B 0.00
Metagenomi (MGX) United States $0.083B 0.00
Unicycive Therapeutics (UNCY) United States $0.079B 0.00
Prelude Therapeutics (PRLD) United States $0.076B 0.00
Dominari Holdings (DOMH) United States $0.074B 0.00
Assertio Holdings (ASRT) United States $0.073B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.071B 0.00
Gain Therapeutics (GANX) United States $0.068B 0.00
Nutriband (NTRB) United States $0.067B 0.00
PMV Pharmaceuticals (PMVP) United States $0.066B 0.00
Lite Strategy (LITS) United States $0.066B 0.00
Acrivon Therapeutics (ACRV) United States $0.063B 0.00
Wellgistics Health (WGRX) United States $0.062B 0.00
PolyPid (PYPD) Israel $0.060B 0.00
BioNxt Solutions (BNXTF) Canada $0.060B 0.00
Fractyl Health (GUTS) United States $0.055B 0.00
Talphera (TLPH) United States $0.054B 0.00
NRx Pharmaceuticals (NRXP) United States $0.053B 0.00
Plus Therapeutics (PSTV) United States $0.051B 0.00
Jupiter Neurosciences (JUNS) United States $0.047B 0.00
ElectroCore (ECOR) United States $0.047B 0.00
Century Therapeutics (IPSC) United States $0.047B 0.00
Rafael Holdings (RFL) United States $0.046B 0.00
Karyopharm Therapeutics (KPTI) United States $0.045B 0.00
FibroGen (FGEN) United States $0.044B 0.00
Telomir Pharmaceuticals (TELO) United States $0.044B 0.00
Tempest Therapeutics (TPST) United States $0.042B 0.00
Inotiv (NOTV) United States $0.040B 0.00
Mural Oncology (MURA) Ireland $0.036B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.035B 0.00
Liminatus Pharma (LIMN) United States $0.035B 0.00
Klotho Neurosciences (KLTO) United States $0.034B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.034B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.033B 27.38
Iterum Therapeutics (ITRM) Ireland $0.028B 0.00
Scienture Holdings (SCNX) United States $0.026B 0.00
SCYNEXIS (SCYX) United States $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.025B 0.00
Citius Pharmaceuticals (CTXR) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.021B 0.00
Vyome Holdings (HIND) United States $0.021B 0.00
Mangoceuticals (MGRX) United States $0.019B 0.00
Natural Alternatives (NAII) United States $0.018B 0.00
Vivos Therapeutics (VVOS) United States $0.017B 0.00
Mannatech (MTEX) United States $0.017B 0.00
CASI Pharmaceuticals (CASI) China $0.016B 0.00
Heatwurx (PCSA) United States $0.016B 0.00
TherapeuticsMD (TXMD) United States $0.015B 0.00
BioLineRx (BLRX) Israel $0.014B 0.00
Traws Pharma (TRAW) United States $0.014B 0.02
Lipocine (LPCN) United States $0.014B 0.00
Ainos (AIMD) United States $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.013B 0.00
ProPhase Labs (PRPH) United States $0.012B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.011B 0.00
BioVie (BIVI) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
VYNE Therapeutics (VYNE) United States $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.008B 0.00
Lyra Therapeutics (LYRA) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Aptorum Group (APM) United Kingdom $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Nuvilex (PMCB) United States $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
CDT Equity (CDT) United States $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Indaptus Therapeutics (INDP) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
NewcelX (NCEL) Switzerland $0.001B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Indivior (INDV) United States $0.000B 16.26
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00